Kornimate/medical-research-clean huggingface dataset:
three phase physical therapy in children with relapsed club foot after ponseti treatment

Conditions: Club Foot

Summary: clubfoot, or congenital talipes equinovarus (ctev), is a condition where a baby is born with one or both feet twisted inward and downward due to abnormal fetal foot development. its estimated global prevalence is 1 in 1,000 live births, varying across populations. relapsed clubfoot, a recurrence after initial correction, may occur due to incomplete treatment, noncompliance, muscle imbalance, or natural growth. treatment involves surgical and non-surgical interventions, including soft tissue releases, osteotomies, and external fixation devices. the ponseti method, a non-surgical approach, is commonly used in infants, with post-treatment physiotherapy focusing on three phases to optimize foot function. this holistic approach aims to achieve the best long-term outcomes for children with clubfoot. this 6-month randomized clinical trial at psrd hospital aims to assess the effectiveness of three-phase physical therapy versus conventional physiotherapy in treating clubfoot. with a sample size of 19 participants and a 10% attrition rate, the study involves children aged 3-10 previously treated with the ponseti method. data collection includes, one-leg standing and sit-to stand tests, pirani score and the oxford ankle foot questionnaire. the three-phase therapy consists of joint mobilization, kinesio taping, and functional exercises over three months, with a focus on improving balance and proprioception.


Eligibility criteria:
inclusion criteria: * having unilateral and bilateral club foot * age between 3-10 year * previously treated with ponseti method * children fall under grade ii and iii according to classification of relapse pattern exclusion criteria: * children who were diagnosed with arthrogryposis multiplex congentia * children with spastic equinovarus * children who had multiple surgical operation

Keywords: club foot ponseti technique three-phase physical therapy
study of nitazoxanide in the treatment of chronic hepatitis c

Conditions: Chronic Hepatitis C

Summary: this study will evaluate the effect of treatment with 24 weeks nitazoxanide monotherapy on end of treatment virologic response, sustained virologic response, reduction of quantitative serum hcv rna, changes in alt and safety parameters.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * chronic hepatitis c infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-hcv-antibodies and a positive quantitative rt-pcr amplification of hcv rna. * chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis. exclusion criteria: * patients unable to take oral medications. * use of interferon alpha within 90 days or ribavirin within 30 days prior to enrollment. * females of child bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active. * any investigational drug therapy within 30 days prior to enrollment. * patients with other causes of liver disease. * patients co-infected with hepatitis a virus, hepatitis b virus or hepatitis d virus based on enzyme immunoassay. * patients with history of alcoholism or with an alcohol consumption of \>40 grams per day. * patients who are clinically unstable. * patients with any concomitant condition that, in the opinion of the investigator would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed. * history of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets.

Keywords: chronic hepatitis c
observational prospective study on behavioral outcomes of children with autism spectrum disorder (asd) in comparison to those without neurodevelopmental diagnoses

Conditions: Autism Spectrum Disorder; Anesthesia

Summary: autism spectrum disorder (asd) is the fastest growing neurodevelopmental disorder in the world. approximately 1% of the population worldwide is affected by this disorder. children with asd exhibit some very stereo-typical behaviors. their daily functionality depends on very rigid and predictable schedules and routines. any changes in their schedules can often trigger negative emotional outbursts. the need to come to the hospital for procedures can be one such trigger. the purpose of this study is to examine the post anesthesia behavior outcomes of children with asd.


Eligibility criteria:
inclusion criteria: * patients aged 2 years through 17 years of age scheduled for a procedure with anesthesia at boston children's hospital * patients must have a diagnosis of autism spectrum disorder (asd) according to the dsm iv and dsm v (autism group) or an asa score of i or ii and no history of neurodevelopmental concerns (control group) exclusion criteria: -families who are not able to read and speak english well enough to complete the validated surveys
population pharmacokinetics of anti-tuberculosis drugs in children with tuberculosis

Conditions: Tuberculosis

Summary: this study is based on the hypothesis that the pharmacokinetics of anti-tuberculosis drugs in tb children are different from adults. the investigators aim to study the population pharmacokinetics of children receiving the anti-tuberculsis drugs for treatment of tb. in this study, the investigators will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. in addition, the investigators also want to correlate use of anti-tuberculsis drugs with treatment effectiveness and incidence of adverse effects in children. this novel knowledge will allow better and more rational approaches to the treatment of tb in children. it will also set the foundation for further studies to improve anti-tuberculosis drug therapies for children.

1.establish population pharmacokinetic (ppk) models of each anti-tuberculsis drug in children by nonlinear mixed effect modeling (nonmem). 1. at different timepoint after anti-tuberculsis drug administration, plasma samples of 100 children will be collected from neonatal intensive care unit (nicu) and pneumology department for each drug. the clinical information includes demography, medication, concentration data, blood biochemical parameters and so on . 2. plasma samples will be tested by high performance liquid chromatography (hplc). 3. ppk models of anti-tuberculsis drug will be established by nonmem program. 4. the reliability and stability of the ppk model will be evaluated by 1000 times of bootstrap procedure and normalized predictive distribution error (npde). 2.evaluation of the clinical feasibility and safety of individualized dosing. 1. according the results of ppk models, the investigators will use dosages recommended in models to cure tb children in prospective studies. for anti-tuberculsis drug, 50 children will be collected. 2. the investigators will compare the therapeutic effects and safety between children with conventional therapies and children with individualized therapies, including proportions of children with effective drug concentration, improvement speed of of children, liver and kidney functions of of children, adverse reactions of drugs and so on.

Eligibility criteria:
inclusion criteria: * children (0-18 years old) with anti-tuberculosis therapy against tb. * the anti-tuberculsis therapy includes drugs commonly used in children infectious diseases * informed consent signed by the parents and/or guardians. exclusion criteria: * anti-tuberculosis drugs aren't involved in the therapies of children. * it is unable to provide complete medical records or the current condition cannot accept the study process. * patients are allergic to anti-tuberculsis drugs. * parents and/or guardians do not agree to participate in this study.
serranator recoil study

Conditions: Peripheral Arterial Disease; Critical Limb Ischemia

Summary: the study objective is to assess the ability to define and measure post treatment recoil in infrapopliteal arteries. preliminary evidence as to the differences between serration angioplasty and standard balloon angioplasty as defined by post treatment recoil, lumen gain, and dissection will be collected.

multi-center, feasibility study treating up to 20 atherosclerotic lesions in the infrapopliteal arteries. the study will capture angiographic imaging (pre, during, post, and post 15 mins) for all lesions, and a subset (up to 10) of ivus imaging data (pre, post, and post 15 mins), to compare serration angioplasty vs standard angioplasty and its effects on vessel recoil and final diameter stenosis.

Eligibility criteria:
inclusion criteria: 1. male or female of \>18 years old. 2. women of childbearing potential must have a negative urine pregnancy test within 7 days of index procedure. 3. subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and comply, and has signed the consent form. 4. subject has rutherford clinical category 3, 4, 5, or 6. angiographic inclusion criteria: 1. target lesion(s) has stenosis \>70% by visual assessment; 2. de-novo, or non-stented re-stenotic lesions; 3. reference vessel diameter is between 2.5 mm and 3.5 mm, inclusive; 4. target lesions involve infrapopliteal tibial arteries including pedal; 5. a target lesion may consist of one long or multiple serial lesions that are up to and including 12 cm in length; 6. if a second lesion is identified in another vessel, the second lesion can also be treated and if treated will be treated with the alternate treatment. exclusion criteria: 1. evidence of aneurysm or acute thrombus in the target vessel. 2. subject has an allergy to contrast medium that cannot be pretreated. 3. subject is pregnant or breastfeeding. angiographic exclusion criteria: 1. acute total occlusions; evidence of acute thrombus formation by angiography. 2. in-stent restenotic lesions. 3. inability to cross the lesion with the assigned study device. 4. treatment of target lesion with atherectomy.
effect of peflow on pfm function recovery of postpartum women

Conditions: Pelvic Floor Muscle Weakness; Rehabilitation

Summary: the purpose of this study is to explore the correlation between women's pelvic floor function with their overall state of bodily functions, including body composition, physical activity levels, trunk muscle endurance, body posture, vaginal and gut microbes. the main intervention of this study is a set of global training which includes the strength, endurance, flexibility, stability and flexibility training on the diaphragm, abdominal, lower back, as well as pelvic floor muscles, on the basis kegel training. the primary destination of global training is to shorten the cycle of postpartum pelvic floor functional recovery, improve the effect of maternal training, and convenient in clinical promotion.

training for 2 times a week, for 12 weeks leading by a specific physiotherapist.the training intensity was evaluated by rpe self-induced fatigue scale.

Eligibility criteria:
inclusion criteria: * newly born women within 42 days to 3 months after delivery, after the end of puerperium, initial postpartum review and pelvic floor professional outpatient screening, found that pelvic floor muscle strength decreased (oxford oxford muscle strength ≤ grade 3); * healthy before pregnancy without pregnancy complications; * convenient transportation, familiar with the internet; * be in good condition and be able to complete the exercise program; * complete clinical baseline data; * agreed to conduct the study and signed the informed consent. exclusion criteria: * patients with stage ⅲ and ⅳ pelvic organ prolapse; * severe urinary incontinence; * lochia, vaginal bleeding and pregnancy; * serious medical diseases, such as cardiac dysfunction who wear pacemakers, neurological diseases, cognitive impairment and other pathological conditions; * cannot complete the intervention program;

Keywords: postpartum global training rehabilitation pelvic floor muscle
telerehabilitation in patients with bronchiectasis

Conditions: Bronchiectasis

Summary: it is to determine the effectiveness of pulmonary rehabilitation by telerehabilitation method in bronchiectasis patients. the cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as telerehabilitation exercise group (trgr) and control group (cgr).

patients diagnosed with bronchiectasis by hrct by a chest diseases specialist and referred to pulmonary rehabilitation by determining the severity of bronchiectasis with the modified reiff score and bronchiectasis severity index score will be included in the study. the cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as telerehabilitation exercise group (trgr) and control group (kgr). trgr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone. as for the kgr group, a pulmonary rehabilitation information brochure will be given to after the initial evaluation. they will be asked to do the exercises on the brochure. the exercise period will be 8 weeks for both groups. standard medical treatments for both groups will continue.

Eligibility criteria:
inclusion criteria: * aged 18 and over * diagnosed with bronchiectasis by hrct * stable clinical state at the time of admission without infection or exacerbation in the previous 3 weeks * know how to use technological devices exclusion criteria: * a history of effort-related syncope or any comorbidity (such as severe orthopedic or neurological deficits or unstable heart disease) that precludes exercise training * patients with systemic diseases other than bronchiectasis that also affect the lungs, such as systemic lupus erythematosus, infection, interstitial lung disease, lung cancer, heart and kidney failure, which will cause shortness of breath * having balance problems that prevent them from doing exercises * participation in a pulmonary rehabilitation program within the past 12 months

Keywords: bronchiectasis pulmonary rehabilitation telerehabilitation
the soundscar study the soundscar study

Conditions: Ventricular Tachycardia; Ischemic Cardiomyopathy

Summary: prospective, non-randomized, single-arm study to assess the accuracy of intracardiac echocardiography (ice) for characterization of arrhythmogenic substrate in patients with ischaemic cardiomyopathy undergoing ventricular tachycardia (vt) ablation

ice imaging during vt ablation is currently largely used for definition of cardiac anatomy. the role of the technique to specifically define scar and arrhythmogenic substrate has not been systematically evaluated. the aim is to assess the efficacy of the technique to accurately define the arrhythmogenic substrate.

Eligibility criteria:
inclusion criteria: * prior heart attack (myocardial infarction) with evidence from prior non-invasive imaging demonstrating regions of the heart with reduced heart muscle function (myocardial hypokinesia/akinesia/thinning) in the absence of a non-heart attack-related (non-ischaemic) cause * age over 18 years * one of the following abnormal heart rhythm (vt) events within last 6 months: * ≥3 episodes of vt treated with therapeutic rapid pacing from an implantable cardiac defibrillator (antitachycardia pacing \[atp\]) * ≥1 appropriate shocks from an implantable cardiac defibrillator * ≥3 episodes of abnormal heart rhythm (vt) within 24 hours * sustained vt below the detection rate of the implantable cardiac defibrillator (documented by ecg/cardiac monitor) * sustained abnormal heart rhythm (vt) in the absence of icd which is documented by ecg/cardiac monitor * patients in whom ice imaging is planned for the clinical vt ablation procedure (clinical indication) exclusion criteria: * patient unable or unwilling to provide informed consent. * acute heart attack (acute coronary syndrome with acute thrombus diagnosed by coronary angiography, or dynamic st segment changes demonstrated on ecg) or another reversible cause of abnormal heart rhythm (vt) - e.g. electrolyte abnormalities or drug-induced abnormal heart rhythms * ineligible for ablation (known to have protruding clot in the chamber of interest (left ventricular thrombus), or have implanted mechanical aortic and mitral valves) * had recent coronary bypass surgery (\< 3 months) or percutaneous coronary intervention (\<3 months) * pregnant patients (pregnancy test will be performed in patients who are of childbearing age who are not on an effective contraceptive prior to all vt ablation procedures) * had recent coronary bypass surgery (\< 3 months) or percutaneous coronary intervention (\<3 months)

Keywords: catheter ablation
a survey on postoperative pain (pop) experience in asian patients.

Conditions: Postoperative Pain

Summary: pain management is becoming an important ethical responsibility of the medical profession and a focus of the health care system. however, there are limited literature evaluate the postoperative pain experience and management in our local setting.

we need to identify those patients who, from a demographic, psychology and surgical viewpoint, are more at risk of experiencing postoperative pain.

Eligibility criteria:
inclusion criteria: * 1. adult with age ≥ 18 who undergo operation exclusion criteria: * 1. refused to give informed consent

Keywords: pain postoperative
effect of nac on preventing chemo-related cognitive impairments in ovarian ca pts treated w/ pbt

Conditions: Ovarian Cancer; Cognitive Impairment

Summary: this is a phase i, dose-escalation and phase ii dose-expansion clinical trial determining the maximum tolerated dose (mtd) and safety and tolerability of adding n-acetyl-cysteine (nac) to ovarian cancer patients who are receiving a platinum-based therapy (pbt). this study will investigate whether nac will mitigate chemotherapy-related cognitive impairment (crci).


Eligibility criteria:
inclusion criteria: post-menopausal females (as defined by lack of menstruation for 12 months or status post oophorectomy) * histologic or pathologic diagnosis of stage iii-iv epithelial ovarian, fallopian tube, or primary peritoneal cancer * eastern cooperative oncology group (ecog) ≤2 * life expectancy \> 1 year * status post cytoreductive surgery for ovarian cancer or with planned cytoreductive surgery if treated with neoadjuvant chemotherapy * prescribed a minimum of six cycles of platinum-based chemotherapy * adequate organ function as defined below: 1. hemoglobin \> 9 g/dl 2. leukocytes \>1,500/mcl 3. absolute neutrophil count \> 1,000/mcl 4. platelets \> 125,00/mcl 5. total bilirubin within normal institutional limits 6. aspartate aminotransferase (ast)/alanine aminotransferase (alt) \< 2.5 x institutional upper limit of normal 7. serum creatinine \< 1.5 mg/dl. exclusion criteria: * prior history of any cancer (other than non-melanoma skin cancer) * chemotherapy, radiation therapy, or erythropoietin treatment within the last 6 months * prior severe head injury * has a history of dementia or other neurodegenerative disorders * has an uncontrolled, treatment-resistant depression or other severe psychiatric illnesses * presence of known brain metastases * has an active infection requiring treatment * known immunosuppressive disease * has active systemic autoimmune diseases such as lupus * receipt of systemic immunosuppressive therapy * known human immunodeficiency virus (hiv) infection, hepatitis b or hepatitis c * pregnant of breastfeeding.

Keywords: chemotherapy-related cognitive impairments
safety study of the vega uv-a system to treat ectasia

Conditions: Ectasia

Summary: the purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (cxl) when used to treat ectasia.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosis of ectasia * presence of central or inferior steepening * topography consistent with ectasia * bscva 20/20 or worse * if contact lens wearer; removal of contact lenses for required period of time * signed informed consent * willingness and ability to comply with schedule for follow-up visits exclusion criteria: * previous ocular condition that may predispose the eye for future complications or prevent the possibility of improved vision * history of chemical injury or delayed epithelial healing * a known sensitivity to study medications * nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests * a condition that would interfere with or prolong epithelial healing * presence or history of any other condition or finding that makes the patient unsuitable for treatment
corneal stroma implantation for the treatment of keratoconus

Conditions: Keratoconus

Summary: the purpose of this study is to determine whether corneal stroma implantation is effective in the treatment of keratoconus.

keratoconus is a corneal disease with the progressive thinning of the central corneal stroma. the main treatment methods are corneal transplantation, corneal collagen cross-linking, etc. the effect of corneal collagen cross-linking is limited, and the lack of donor cornea is really a very big problem. in this pilot project, investigators would like to study whether corneal stroma implantation can increase the biomechanics of the cornea, which can, to some extent, delay the progress of keratoconus. this will allowed us to determine if useful data can be obtained, and if so, the donor cornea can be greatly saved.

Eligibility criteria:
inclusion criteria: 1. advanced and completed keratoconus patients 2. voluntarily signed informed consent 3. no surgery and anesthesia contraindications exclusion criteria: 1. acute edema of cornea 2. primary keratoconus patients 3. the patients combined systemic diseases 4. reject study and follow visit 5. cannot tolerate surgery or anesthesia